Combined analysis of ZAP-70 and CD38 expression in sudanese patients with B-cell chronic lymphocytic leukemia

• Published in: BMC research notes 2019-05, Vol.12 (1), p.282-6, Article 282
• Main Authors: Basabaeen, Ameen Abdulaziz, Abdelgader, Enaam Abdelrhman, BaHashwan, Othman Saeed, Babekir, Ebtihal Ahmed, Abdelateif, Nour Mahmoud, Bamusa, Salem Ahmed, Abdelrahim, Saadia Osman, Altayeb, Osama Ali, Fadul, Eman Abbass, Ibrahim, Ibrahim Khider
• Format: Article
• Language: English
• Subjects: ADP-ribosyl Cyclase 1 - blood; ADP-ribosyl Cyclase 1 - genetics; ADP-ribosyl Cyclase 1 - immunology; Adult; Aged; Agent Orange; Analysis; B cells; B-CLL; B-Lymphocytes - immunology; B-Lymphocytes - pathology; Binet; Biological markers; Biomarkers, Tumor - blood; Biomarkers, Tumor - genetics; Biomarkers, Tumor - immunology; Blood tests; Cancer; CD38; CD38 antigen; Chronic lymphocytic leukemia; Combined; Cross-Sectional Studies; Development and progression; Diagnosis; EDTA; Female; Flow cytometry; Gene Expression; Glycoproteins; Hematology; Humans; Immunophenotyping; Leukemia; Leukemia, Lymphocytic, Chronic, B-Cell - diagnosis; Leukemia, Lymphocytic, Chronic, B-Cell - genetics; Leukemia, Lymphocytic, Chronic, B-Cell - immunology; Leukemia, Lymphocytic, Chronic, B-Cell - pathology; Lymphatic leukemia; Lymphocytes; Lymphocytes B; Lymphocytic leukemia; Male; Medical prognosis; Medical research; Membrane Glycoproteins - blood; Membrane Glycoproteins - genetics; Membrane Glycoproteins - immunology; Middle Aged; Mutation; Neoplasm Staging; Patients; Prospective Studies; Protein kinases; Rai; Research Note; Splenomegaly; Splenomegaly - diagnosis; Splenomegaly - genetics; Splenomegaly - immunology; Splenomegaly - pathology; Sudan; ZAP-70; ZAP-70 protein; ZAP-70 Protein-Tyrosine Kinase - blood; ZAP-70 Protein-Tyrosine Kinase - genetics; ZAP-70 Protein-Tyrosine Kinase - immunology
• ISSN: 1756-0500; 1756-0500
• DOI: 10.1186/s13104-019-4319-8

To investigate the ZAP-70 and CD38 expressions and their combined expressions in Sudanese B-CLL patients and their relationships with clinical and hematological characteristics as well as the disease staging at presentation. In the present cross-sectional descriptive study, analysis of ZAP-70 expression showed that 36/110 (32.7%) patients positively expressed ZAP-70 and insignificant higher presentation in intermediate and at advanced stages as well as no correlation was seen with hematological parameters and clinical features compared with negatively ZAP-70, on the other hand, 41/110 (37.3%) were CD38 and no significant correlation was shown with the stage at presentation, clinical characteristics (except Splenomegaly, P = 0.02) and hematological parameters. However, in combined expressions of both ZAP-70 and CD38 together, 20/110 (18.2%) were concordantly ZAP-70 /CD38 , 53/110 (48.2%) concordantly ZAP-70 /CD38 and 37/110 (33.6%) either ZAP-70 or CD38 , and these three groups showed insignificant correlation with clinical (except Splenomegaly, P = 0.03) and hematological parameters, and the stage at presentation. Our data showed the combined analysis of these two markers, lead to classify our patients into three subgroups (either concordant positive, negative or discordant expressions) with statistically insignificant correlation with clinical presentation (except Splenomegaly), hematological parameters and stage at presentation of B-CLL patients.